It has been demonstrated that biological therapy, such as Adalimumab, Infliximab, and Certolizumab, improves the quality of life for patients with IBD by blocking the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α). The gene discussed is TNF; the disease is irritable bowel syndrome.